Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients

Tamburino, Corrado; Ciriminna, Saverio; Barbagallo, Rossella; Galassi, Alfredo R.; Ussia, Gianpaolo; Capranzano, Piera; Tagliareni, Francesco; Tolaro, Salvatore; Nicosia, Antonino; Stabile, Amerigo; Grassi, Rosario; Fiscella, Antonio; Patti, Aldo; Saccone, Giovanni

doi:10.2459/jcm.0b013e32815aa7d1

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The extensive angiographic follow-up, although it is known to accentuate the rates of repeat revascularization compared with clinical follow-up alone [11], has provided important findings on the actual performance of the new device even in asymptomatic patients, showing a significant late loss and very high rate of TLR and binary restenosis, which were different from those reported for other unselected populations undergone to DES implantation [1][2][3]12].…”

Section: Discussioncontrasting

confidence: 47%

Real world safety and efficacy of the Janus tacrolimus‐eluting stent: Long‐term clinical outcome and angiographic findings from the tacrolimus‐eluting stent (TEST) registry

Tamburino¹,

Salvo²,

Capodanno³

et al. 2009

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 47%

Real world safety and efficacy of the Janus tacrolimus‐eluting stent: Long‐term clinical outcome and angiographic findings from the tacrolimus‐eluting stent (TEST) registry

Tamburino¹,

Salvo²,

Capodanno³

et al. 2009

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

show abstract

“…Another important aspect to note is the lack of data from the Brazilian population, whose own cultural and social characteristics influence the adherence to treatment, besides the fact that its genetic composition differs from populations assessed in the large registries of the United States and Europe. [3][4][5][6] The aim of the present study was to evaluate the initial and late events of a non-selected cohort of patients undergoing DES implantation, comparing diabetic and non-diabetic patients.…”

Section: Definitions and Primary Outcomementioning

confidence: 99%

Resultados iniciais e tardios de diabéticos tratados com stents farmacológicos do Registro Safira

Flávio

Marchini

Salman

et al. 2013

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

Background: The percutaneous treatment of coronary artery disease has been revolutionized by the use of drug-eluting stents (DES). However, its use in the daily practice involves patients with more complex clinical and angiographic characteristics than those found in randomized trials. This registry was designed to characterize diabetic patients and their outcomes following DES implantation in our country. Methods: Prospective single-center registry enrolling consecutive patients after DES implantation. Clinical, angiographic and procedurerelated data, as well as early and long-term outcomes were recorded. The primary endpoint, including cardiac death, myocardial infarction or target lesion revascularization, was compared between diabetics and non-diabetics. Results: We evaluated 1,670 patients treated with DES from 2002 to 2012 with a follow-up of 3.2 ± 2.5 years. One third of the patients were diabetic and had lower event-free survival when compared to non-diabetic patients (79.4% vs. 82.6%; P = 0.015). The adjusted odds ratio, however, was 1.22 (95% CI, 0.89-1.69) and was not significant. A significantly lower event-free survival was observed in the subgroup of patients receiving insulin, whereas it was similar for diabetic and nondiabetic patients in the subgroup not receiving insulin (68.7% vs. 83.9% vs. 82.8%, respectively; P < 0.01). The adjusted odds ratio was 1.72 (95% CI, 1.13-2.63) higher for diabetic patients receiving insulin when compared to the remaining patients.

show abstract

“…Thus, since the benefit of DES is higher in patients at high risk of restenosis, the difference in cost-effectiveness of DES versus BMS could be overestimated, urging us to be cautious when we extend these findings out of their context. For example, a statistical analysis of unpublished data from the Sicilian DES registry 11 with the use of decisional models reached a different result, with evidence of a substantial economic benefit of DES, especially in patients who otherwise would be candidates for CABG.…”

mentioning

confidence: 99%

The Sicilian Drug-eluting Stent Registry – Risk–Benefit and Cost-effectiveness Analyses of Drug-eluting Stents versus Bare-metal Stents

Tamburino¹,

Capodanno²

2008

Interventional Cardiology Review

Self Cite

View full text Add to dashboard Cite

He is President of the Italian Society of Invasive Cardiology and a member of the Board of Trustees of the Society for Cardiovascular Angiography and Interventions (SCAI). He introduced the technique of endomyocardial biopsy and mitral valvuloplasty to Sicily and has performed more than 12,000 interventional procedures with these applications on coronary angioplasty and coronary stent implantation. Professor Tamburino was the first in Italy to implant a percutaneous aortic valve on patients who cannot undergo surgical interventions.

show abstract

Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients

Abstract: Drug-eluting stents appear to be safe and associated with a low incidence of MACE at 9-month follow-up, even in patients selected for their complexity.

Cited by 6 publications

References 25 publications

Real world safety and efficacy of the Janus tacrolimus‐eluting stent: Long‐term clinical outcome and angiographic findings from the tacrolimus‐eluting stent (TEST) registry

Real world safety and efficacy of the Janus tacrolimus‐eluting stent: Long‐term clinical outcome and angiographic findings from the tacrolimus‐eluting stent (TEST) registry

Resultados iniciais e tardios de diabéticos tratados com stents farmacológicos do Registro Safira

The Sicilian Drug-eluting Stent Registry – Risk–Benefit and Cost-effectiveness Analyses of Drug-eluting Stents versus Bare-metal Stents

Contact Info

Product

Resources

About